CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

MLA

Han, Jianfeng, et al. “CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.” Scientific Reports, July 2015, p. 11483. EBSCOhost, https://doi.org/10.1038/srep11483.

APA

Han, J., Caligiuri, M. A., Yu, J., Chu, J., Keung Chan, W., Wang, Y., Victor, A., Zhang, J., Cohen, J. B., Grandi, P., Glorioso III, J. C., Meisen, W. H., Kim, S., Nakano, I., Kaur, B., Wang, Q.-E., He, X., & Chiocca, E. A. (2015). CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports, 11483. https://doi.org/10.1038/srep11483

Chicago

Han, Jianfeng, Michael A. Caligiuri, Jianhua Yu, Jianhong Chu, Wing Keung Chan, Youwei Wang, Aaron Victor, et al. 2015. “CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.” Scientific Reports, July, 11483. doi:10.1038/srep11483.